Wall Street analysts bullish on Attovia as itch drug data fuel biotech optimism

Attovia Therapeutics received bullish ratings from Citi, Morgan Stanley, and RBC, with price targets ranging from $30 to $45, citing promising early data for its chronic-itch drug ATTO-1310 and its antibody platform. The stock, trading around $21, has significant upside potential according to analysts. The company has $420M in cash post-IPO, reducing near-term financing concerns. Analysts caution about clinical-stage risks, including trial outcomes and competition.

Original reporting
Published Aug 31, 2026, 1:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 31, 2026, 1:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$ATTO
Bullish
high confidence
Mentioned
$ATTO
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ATTOBullishMed
01

Why it matters

Analyst upgrades and Phase 1b efficacy data provide a catalyst for stock movement.

02

Market read

New analyst coverage and early trial data create a short-term trading opportunity for ATTO.

03

What to watch

Small Phase 1b cohort size and competition from established IL-31 drugs.

Relevance 8/10Novelty 8/10Timing: published today

Background

Attovia Therapeutics recently completed its IPO and is cash-rich, targeting chronic itch treatments.

Company-level read

Ticker impact

$ATTOBullishHigh confidence
Context

Analyst initiation with Buy/High Risk rating and $30-$45 price targets after release of Phase 1b data for ATTO-1310.

Expected impact

Potential upside of 30-50% if data spurs investor interest.

Evidence & confidence

New clinical data and multiple analyst upgrades provide fresh, material information for traders.

Market effects

Boosts optimism for IL-31 pathway biotech sector.

Positive for US biotech market.

Limited to biotech investors.

Counterpoint

Early-phase data may not translate to later trials; valuation could be overstated.

Key entities

  • Attovia Therapeutics

    Clinical-stage biotech developing IL-31 antibody therapies.

  • Citi

    Initiated coverage with Buy/High Risk rating.

  • Morgan Stanley

    Started coverage at Overweight.

  • RBC Capital Markets

    Initiated coverage at Outperform.

Related articles

$ATTOMed

Attovia Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update

Attovia Therapeutics, Inc. (ATTO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Attovia Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update Announced positive topline 12-week Phase 1b results for ATTO-1310 in patients with chronic pruritus (CP) and high-itch atopic dermatitis (AD) Initiation of global Phase

$ATTOMedAI 8/10

Attovia Therapeutics Reports Sustained Itch Relief in Small Study, Plans Phase 2 Trials

Attovia Therapeutics (ATTO) reported sustained itch relief in a small study for its drug ATTO-1310, with no serious adverse events related to the treatment. The company plans phase 2 trials with 300 patients in one study and 255 in another, aiming for quarterly maintenance dosing. Attovia expects data from a phase 1b study in 2027 and has a cash runway into 2030. The company is developing antibody-based treatments for immune-mediated and inflammatory diseases.

$ATTOHighAI 9/10

Attovia reports 12-week data from ATTO-1310 itch therapy trial

Attovia Therapeutics (NASDAQ:ATTO) reported 12-week Phase 1b trial results for ATTO-1310, an anti-IL-31 therapy. In chronic pruritus patients, 82% of treated patients saw a 4-point reduction in itch versus 22% with placebo. In high-itch atopic dermatitis patients, 44% of treated patients achieved a 4-point reduction versus 75% with placebo. The drug was generally well-tolerated, with plans for Phase 2 trials in 2027.

$ATTOMedAI 8/10

Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Attovia Therapeutics, Inc. (ATTO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update ATTO-1310 demonstrated preliminary clinical proof of concept in chronic pruritus and high-itch atopic dermatitis (AD); complete Phase 1b data expected in Q4 2026 Phase 2 studies of